Surviving the storm: critical care outcomes of chimeric antigen receptor T-cell therapy

Affiliations

¹ Critical Care Medicine Department, National Institutes of Health, Bethesda, MD 20892, USA; Critical Care Department, Mayo Clinic Arizona, Phoenix, AZ, USA.
² Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: nirali.Shah@nih.gov.

Comment

Janhavi Athale et al. Lancet Haematol. 2021 May.

. 2021 May;8(5):e311-e312.

doi: 10.1016/S2352-3026(21)00097-1.

¹ Critical Care Medicine Department, National Institutes of Health, Bethesda, MD 20892, USA; Critical Care Department, Mayo Clinic Arizona, Phoenix, AZ, USA.
² Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: nirali.Shah@nih.gov.

No abstract available

Conflict of interest statement

We declare no competing interests.

Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study.
Azoulay É, Castro P, Maamar A, Metaxa V, de Moraes AG, Voigt L, Wallet F, Klouche K, Picard M, Moreau AS, Van De Louw A, Seguin A, Mokart D, Chawla S, Leroy J, Böll B, Issa N, Levy B, Hemelaar P, Fernandez S, Munshi L, Bauer P, Schellongowski P, Joannidis M, Moreno-Gonzalez G, Galstian G, Darmon M, Valade S; Nine-I investigators. Azoulay É, et al. Lancet Haematol. 2021 May;8(5):e355-e364. doi: 10.1016/S2352-3026(21)00060-0. Lancet Haematol. 2021. PMID: 33894170